Hangzhou Sanofi Minsheng Health Pharmaceutical Co., Ltd

Jinvita, listed in 1984, is the first multi-dimensional element product to be listed in China. According to the nutritional status and eating habits of the Chinese people, the scientific ratio, balanced supplement of 21 vitamins and minerals needed by the human body, using the world-class production line of health products.

"21 jinvita" is a kind of medicine which is mainly composed of 21 kinds of vitamins and trace elements. It is an advanced vitamin supplement. Jinvita contains vitamin C and E, vitamin C can whiten, enhance resistance, anti-aging, vitamin E can soften blood vessels, anti-aging, whitening, can be used for beauty, remove certain stains.

Hangzhou Minsheng Pharmaceutical Co., Ltd., founded in 1926, is one of the four earliest western medicine factories in China. For more than 80 years, Minsheng pharmaceutical has been focusing on the western pharmaceutical industry, witnessing the whole history of Western pharmaceutical industry in China. In 2006, it was awarded the first batch of "China time honored brand" enterprises by the Ministry of Commerce.

The company mainly produces prescription drugs (anti-tumor drugs, anti hepatitis B drugs, cardiovascular drugs), OTC (including vitamins and health care products), large infusion (including special infusion) and API. In 2004, kingvita was recognized as "China famous trademark" and established the leading brand position in the domestic multi-dimensional element supplement market. In addition, the company enjoys a high market reputation in the field of anti-tumor and infusion.

The company has strong product development ability and advanced quality assurance system. Powder injection, freeze-dried powder injection, large volume injection and tablet have obtained GMP certificate. At the same time, the company has been identified by the relevant departments of Hangzhou municipal government as a high-tech enterprise of research and production base of high-efficiency chemical raw materials and various new preparations.

With more than 80 years of accumulation and development, Minsheng pharmaceutical has become a professional and responsible modern pharmaceutical company. The company successfully implemented the leapfrog development strategy from 2002 to 2006. The international development strategy, which has been fully implemented since 2007, will lead the enterprise to a new glory. It is our pursuit to build a century old people's livelihood which is enduring, endless and full of youth and vitality!

Hangzhou Sanofi Minsheng Health Pharmaceutical Co., Ltd., established in 2010, is a joint venture in the field of health pharmaceutical industry jointly established by Sanofi, the world's leading diversified pharmaceutical and health enterprise, and Hangzhou Minsheng Pharmaceutical Group. This marks Sanofi's official entry into the dynamic OTC market in China, which is also the second largest OTC market in the world.

As a leading diversified pharmaceutical and health enterprise in the world, Sanofi expands its global strength through continuous mergers and acquisitions in the field of health medicine. Entering China's health pharmaceutical market has become another pillar of Sanofi's support for China's prevention and health care. Sanofi has set up a joint venture with Minsheng pharmaceutical, a long-term partner, with the aim of covering all markets with brands such as 21 kingvita, so that more Chinese people can enjoy health protection.